Current Management and Future Strategies of Gastric Cancer.
10.3349/ymj.2012.53.2.248
- Author:
Joong Ho LEE
1
;
Kyung Min KIM
;
Jae Ho CHEONG
;
Sung Hoon NOH
Author Information
1. Department of Surgery, Yonsei University College of Medicine, Seoul, Korea. jhcheong@yuhs.ac
- Publication Type:Research Support, Non-U.S. Gov't ; Review
- Keywords:
Stomach neoplasm;
primary prevention;
screening;
gastrectomy;
lymphadenectomy;
biological marker;
molecular therapeutics
- MeSH:
Disease Management;
Gastrectomy;
Humans;
Lymph Node Excision;
Stomach Neoplasms/*diagnosis/drug therapy/etiology/surgery
- From:Yonsei Medical Journal
2012;53(2):248-257
- CountryRepublic of Korea
- Language:English
-
Abstract:
The overall prognosis of gastric cancer has gradually improved over the past decades with growing awareness of potential carcinogens, surveillance programs and early diagnosis, as well as advances in surgical techniques and multimodality treatments. Nevertheless, the outcome of advanced stage disease still remains poor with currently available treatments, and a worldwide consensus on the standard management thereof has not been established. To improve prognosis and quality of life in gastric cancer patients, both standardization and individualization of managements are imperative. Diagnostic tests and surgical procedures need to be further sophisticated and standardized based on more recent evidences from ongoing and future randomized controlled trials, while comprehensive management should be individualized to each patient. Future challenges lie with how to optimize personalized therapies by deciphering biological complexity of gastric cancer and incorporating molecular biomarkers in clinical practice to forecast prognosis and to guide targeted therapeutics in adjunct to current standards of care.
